Literature DB >> 23605289

When clinical trials fail to address treatment gaps: the failure of niacin-laropiprant to reduce cardiovascular events.

Robert S Rosenson1, Antonio M Gotto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23605289     DOI： 10.1007/s11883-013-0332-x

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


× No keyword cloud information.
  16 in total

1.  Clofibrate and niacin in coronary heart disease.

Authors: 
Journal:  JAMA       Date:  1975-01-27       Impact factor: 56.272

2.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

3.  Clinical trials of HDL cholesterol-raising therapy: what have we learned about the HDL hypothesis from AIM-HIGH?

Authors:  Robert S Rosenson
Journal:  Curr Atheroscler Rep       Date:  2012-06       Impact factor: 5.113

4.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.

Authors:  B G Brown; X Q Zhao; A Chait; L D Fisher; M C Cheung; J S Morse; A A Dowdy; E K Marino; E L Bolson; P Alaupovic; J Frohlich; J J Albers
Journal:  N Engl J Med       Date:  2001-11-29       Impact factor: 91.245

5.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.

Authors:  G Brown; J J Albers; L D Fisher; S M Schaefer; J T Lin; C Kaplan; X Q Zhao; B D Bisson; V F Fitzpatrick; H T Dodge
Journal:  N Engl J Med       Date:  1990-11-08       Impact factor: 91.245

6.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

7.  Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.

Authors:  Allen J Taylor; Lance E Sullenberger; Hyun J Lee; Jeannie K Lee; Karen A Grace
Journal:  Circulation       Date:  2004-11-10       Impact factor: 29.690

8.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

9.  Extended-release niacin or ezetimibe and carotid intima-media thickness.

Authors:  Allen J Taylor; Todd C Villines; Eric J Stanek; Patrick J Devine; Len Griffen; Michael Miller; Neil J Weissman; Mark Turco
Journal:  N Engl J Med       Date:  2009-11-15       Impact factor: 91.245

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321
View more
  3 in total

Review 1.  Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients.

Authors:  Szu-chi Chen; Chin-Hsiao Tseng
Journal:  Rev Diabet Stud       Date:  2013-08-10

Review 2.  Niacin, an old drug with a new twist.

Authors:  Wen-Liang Song; Garret A FitzGerald
Journal:  J Lipid Res       Date:  2013-08-15       Impact factor: 5.922

3.  HDL, Atherosclerosis, and Emerging Therapies.

Authors:  Anouar Hafiane; Jacques Genest
Journal:  Cholesterol       Date:  2013-05-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.